NanOlogy
  • Home
  • About
  • Technology
  • Development
    • Investigational Drugs
    • Pipeline
    • Clinical Trials
    • Partnering Opportunities
  • News & Publications
    • Recent News Highlights
    • Press Release Archives
    • NanOlogy In the News
    • Presentations & Publications Archive
  • Contact Us
    • Partnering Opportunities
    • Physicians and Patients
Post placeholder image
January 15, 2019 in Presentations

SABCS 2018 Poster: Phase 1/2 Study of Topical SOR007 for Cutaneous Metastases

NanOlogy 0 Like Post Comments Off on SABCS 2018 Poster: Phase 1/2 Study of Topical SOR007 for Cutaneous Metastases

SABCS 2018 Poster: Phase 1/2 Study of Topical SOR007 for Cutaneous Metastases

Read More
NanOlogy

NanOlogy investigational drugs have not yet been proven to be safe and effective in accordance with the requirements of the U.S. FDA and are not approved by FDA or any other jurisdiction for commercial distribution. NanOlogy, NanoPac, and NanoDoce are trademarks of NanOlogy, LLC.    Purcision is a trademark to CritiTech, Inc.  © NanOlogy LLC      Legal